J Erik Fyrwald bought $1.0M of Eli Lilly and (LLY)
Executed Aug 12 2025, disclosed Aug 12 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 12 2025), the stock returned +18.3% (delay-adjusted); from the execution session (Aug 12 2025), +18.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
J Erik Fyrwald (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in International Flavors & Fragrances Inc. (IFF). Across 1 priced purchase filing, the average 21-session return was +1.6% from execution and +3.8% from disclosure (delay-adjusted; derived). The largest single filing was $933K of IFF (13,360 sh × $69.85, as filed), executed Mar 13.
Healthcare · Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Jap…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→